MedTrace Logo

Study to Assess PK/PD Character, Safety/Tolerability of CKD-519 New Formulation in Healthy Male Subject.

NCT02623868 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2016-01-20

No results posted yet for this study

Summary

Study to assess the pharmacokinetic/pharmacodynamic characteristics and safety/tolerability to CKD-519 new formulation in healthy male subjects.

Conditions

Interventions

DRUG

CKD-519 50mg 2Tabs.

after taking Standard meal, CKD-519 50mg 2Tabs. administration.

DRUG

CKD-519 100mg 1Tab.

after taking Standard meal, CKD-519 100mg 1Tab. administration.

DRUG

CKD-519 100mg 1Cap.

after taking Standard meal, CKD-519 100mg 1Cap. administration.

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Ji Young Kim, MD, PhD · Korea University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02623868 on ClinicalTrials.gov